Monopar Therapeutics (MNPR) Shares Outstanding (Weighted Average) (2016 - 2020)

Monopar Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $10.8 million for Q3 2020.

  • For Q3 2020, Shares Outstanding (Weighted Average) rose 16.15% year-over-year to $10.8 million; the TTM value through Sep 2020 reached $10.8 million, up 16.15%, while the annual FY2019 figure was $9.3 million, 0.32% changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2020 was $10.8 million at Monopar Therapeutics, up from $10.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $10.8 million in Q3 2020 and bottomed at $8.3 million in Q1 2017.
  • The 4-year median for Shares Outstanding (Weighted Average) is $9.3 million (2018), against an average of $9.4 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) changed 0.0% in 2019 before it increased 16.15% in 2020.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $8.8 million in 2017, then grew by 5.8% to $9.3 million in 2018, then grew by 0.32% to $9.3 million in 2019, then grew by 15.78% to $10.8 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Shares Outstanding (Weighted Average) are $10.8 million (Q3 2020), $10.6 million (Q2 2020), and $10.6 million (Q1 2020).